Shire plc : Director/PDMR Shareholding
August 22 2017 - 8:00AM
Director/PDMR
Shareholding
August 22,
2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of
transaction by person discharging managerial
responsibilities
| 1. |
Details of the person discharging managerial
responsibilities ("PDMR") / person closely associated them
("PCA") |
| a) |
Name |
Flemming Ornskov |
| 2. |
Reason for the notification |
| a) |
Position / status |
Chief Executive Officer - PDMR |
| b) |
Initial notification / amendment |
Initial notification |
| 3. |
Details of the issuer, emission allowance
participant, auction platform, auctioneer or auction
monitor |
| a) |
Name |
Shire plc |
| b) |
LEI |
54930005LQRLI2UXRQ59 |
| 4. |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted |
| a) |
Description of the financial instrument, type of
instrument |
Shire plc Ordinary Shares of 5 pence each ("Ordinary
Shares")
|
| Identification code |
ISIN: JE00B2QKY057 |
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares |
| c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
| £36.6493 |
8,400 |
| d) |
Aggregated information
- Aggregated volume
- Price |
N/A (single transaction) |
| e) |
Date of the transaction |
August 22, 2017 |
| f) |
Place of the transaction |
London Stock Exchange |
Oliver Strawbridge
Senior Assistant Company
Secretary
For further information please
contact:
| Investor Relations |
|
|
| Ian
Karp |
ikarp@shire.com |
+1 781 482 9018 |
| Robert
Coates |
rcoates@shire.com |
+44 1256 894874 |
| Media |
|
|
| Lisa
Adler |
lisa.adler@shire.com |
+1 617 588 8607 |
| Debbi
Ford |
debbi.ford@shire.com |
+1 617
949 9083 |
NOTES TO
EDITORS
About
Shire
Shire is the leading global
biotechnology company focused on serving people with rare diseases.
We strive to develop best-in-class products, many of which are
available in more than 100 countries, across core therapeutic areas
including Hematology, Immunology, Neuroscience, Ophthalmics,
Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine /
Endocrine and Hereditary Angioedema; and a growing franchise in
Oncology.
Our employees come to work every
day with a shared mission: to develop and deliver breakthrough
therapies for the hundreds of millions of people in the world
affected by rare diseases and other high-need conditions, and who
lack effective therapies to live their lives to the fullest.
www.shire.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Shire plc via Globenewswire
Shire (LSE:SHP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shire (LSE:SHP)
Historical Stock Chart
From Apr 2023 to Apr 2024
